ARO-MAPT-SC is a Phase 1/2a clinical trial evaluating a novel tau-targeting RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals. The trial investigates ARO-MAPT-SC in healthy subjects and patients with early Alzheimer's disease.
This represents a groundbreaking approach to Alzheimer's disease therapy by targeting tau pathology at its source—the genetic level. Unlike antibody-based approaches that clear existing tau protein, RNAi therapeutics can reduce tau production before pathological accumulation occurs.
| Attribute |
Details |
| NCT Number |
NCT07221344 |
| Phase |
Phase 1/2a |
| Status |
Recruiting |
| Sponsor |
Arrowhead Pharmaceuticals |
| Enrollment |
112 participants |
| Start Date |
November 18, 2025 |
| Expected Completion |
June 2027 |
| Location |
Grafton, Auckland, New Zealand |
| Administration |
Subcutaneous injection |
Tau (MAPT - Microtubule-Associated Protein Tau) is a protein that stabilizes microtubules in neurons. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, leading to:
- Neurofibrillary Tangle Formation: Paired helical filaments of hyperphosphorylated tau
- Microtubule Dysfunction: Loss of tau's normal microtubule-stabilizing function
- Synaptic Loss: Tau pathology correlates with synaptic dysfunction
- Neuronal Death: Progressive neurodegeneration follows tau accumulation
Recent research supports the concept that tau pathology spreads prion-like through connected brain regions:
- Template-Driven Misfolding: Pathological tau acts as a template for normal tau
- Synaptic Transmission: Tau spreads across synapses between neurons
- Network-Based Progression: Pathology follows functional brain networks
- Region-Specific Vulnerability: Entorhinal cortex and hippocampus early affected
The relationship between amyloid and tau pathology is complex:
- Amyloid-Independent Tau: Tau pathology can occur without significant amyloid
- Amyloid Potentiation: Amyloid may accelerate tau pathology
- Sequential Model: Amyloid triggers tau which mediates neurodegeneration
- Threshold Effects: Both pathologies must exceed thresholds for clinical symptoms
ARO-MAPT-SC employs RNA interference to reduce tau expression. The mechanism involves several steps:
- TRiM™ Platform: Arrowhead's Targeted RNAi Molecule platform
- Cellular Uptake: siRNA enters cells via endocytosis
- Endosomal Escape: Proprietary chemistry enables release from endosomes
- Guide Strand Selection: One siRNA strand becomes the guide
- RISC Incorporation: The siRNA-RISC complex scans for complementary mRNA
- Catalytic Activity: One RISC complex can destroy multiple mRNA molecules
- Sequence Complementarity: siRNA guide binds to MAPT mRNA
- Endonucleolytic Cleavage: Argonaute protein cuts the mRNA
- mRNA Degradation: Cleaved mRNA is degraded by cellular machinery
- Reduced Protein Translation: Fewer tau protein molecules produced
¶ Advantages Over Antibody Approaches
RNAi offers several potential advantages:
| Feature |
RNAi (ARO-MAPT-SC) |
Antibody Approach |
| Target |
Genetic level (mRNA) |
Protein level |
| Effect |
Reduces production |
Clears existing protein |
| Duration |
Extended with subcutaneous dosing |
Requires repeated infusions |
| Distribution |
TRiM™ enables CNS delivery |
Limited BBB penetration |
| Mechanism |
Gene silencing |
Protein clearance |
Arrowhead's TRiM™ platform represents advances in siRNA delivery:
- Targeting Ligands: Multiple options for tissue-specific delivery
- Endosomal Escape: Enhanced intracellular delivery
- Stability: Improved nuclease resistance
- Manufacturing: Scalable synthetic production
The trial employs a sophisticated adaptive design:
- Healthy Volunteer Cohort: Initial safety assessment
- Single Ascending Doses: Escalating doses to establish MTD
- Multiple Ascending Doses: Assessment of repeat dosing
- Early AD Cohort: Assessment in target population
- Efficacy Cohort: Patients with early AD
- Dose-Optimization: Refine dosing based on PK/PD
- Biomarker Assessment: Tau biomarkers as endpoints
- Age 18-65 years
- Normal cognitive function
- No significant medical conditions
- Informed consent for participation
- Diagnosis: NIA-AA criteria for MCI due to AD or mild AD dementia
- Age: Typical for early AD studies (55-85 years)
- Biomarker Confirmation: Evidence of tau pathology
- Stable Medications: No changes in AD medications for 4 weeks
- Drug: ARO-MAPT-SC
- Route: Subcutaneous injection
- Schedule: Every 4 or 8 weeks
- Duration: Multiple doses over 12 months
- Control: Placebo (saline injection)
- Confirmed early Alzheimer's disease diagnosis
- MMSE score ≥ 20
- Age range typical for early AD studies
- Suitable for subcutaneous delivery
- Able to comply with study procedures
- Significant psychiatric comorbidity
- Unstable medical conditions
- Contraindications to MRI
- Previous participation in tau-targeted trials
- Significant cerebral vascular disease
¶ Safety and Tolerability
- Treatment-Emergent Adverse Events (TEAEs)
- Serious Adverse Events (SAEs)
- Laboratory Abnormalities
- Vital Signs and ECG Changes
- Plasma Concentration: Drug levels over time
- Cerebrospinal Fluid (CSF): Drug penetration assessment
- Half-Life Determination: Dosing interval optimization
- MAPT mRNA Levels: Gene expression changes in CSF cells
- Tau Protein: Total tau and phosphorylated tau in CSF
- Biomarker Correlations: PK/PD relationship
- Cognitive Measures: Change in cognitive performance
- Brain Imaging: Tau PET changes
- Volumetric MRI: Brain atrophy rates
- Functional Outcomes: Activities of daily living
The tau protein hypothesis posits that accumulation of hyperphosphorylated tau protein into neurofibrillary tangles drives neuronal dysfunction and cell death in Alzheimer's disease.
By reducing tau production at the genetic level, ARO-MAPT-SC aims to:
- Decrease Tau Protein Synthesis: Reduce the source of pathological tau
- Reduce Tau Aggregation: Lower substrate for tangle formation
- Slow Disease Progression: Prevent downstream neurodegeneration
- Potentially Reverse Symptoms: If treated early enough
The therapeutic rationale includes:
- Asymptomatic Period: Tau accumulation begins decades before symptoms
- Critical Threshold: Pathological accumulation exceeds clearance capacity
- Early Intervention: Reducing production before irreversible damage
- Disease Modification: Address root cause rather than symptoms
Subcutaneous delivery offers practical advantages:
- Patient Convenience: Office-based injection vs. intravenous
- Extended Exposure: Slower absorption, prolonged drug exposure
- Self-Administration: Potential for at-home dosing
- Dosing Flexibility: Multiple dose strengths available
The trial incorporates comprehensive biomarker assessments:
- Total Tau: Marker of neuronal injury
- Phosphorylated Tau (p-tau181/217): Disease-specific tau pathology
- Neurofilament Light Chain (NfL): Neurodegeneration marker
- Beta-Amyloid: Concomitant AD pathology
- Tau PET: Regional tau burden assessment
- Amyloid PET: Amyloid plaque quantification
- Volumetric MRI: Brain structure measurements
- FDG-PET: Metabolic activity assessment
Several challenges must be addressed:
- Biomarker Validation: Confirm drug reaches target
- Dose Selection: Optimize based on CSF tau reduction
- PK/PD Modeling: Predict effective dosing
- Slow Disease Progression: Requires long trials
- Symptomatic Overlap: Difficult to isolate treatment effect
- Regulatory Acceptance: Biomarker endpoints as surrogates
- Off-Target Effects: Need selectivity for MAPT
- Long-Term Safety: Extended treatment implications
- Tau Reduction Safety: Confirm safety of reduced tau
| Approach |
Example |
Mechanism |
Stage |
Administration |
| ASO |
ARO-MAPT-SC |
MAPT mRNA knockdown |
Phase 1/2a |
Subcutaneous |
| ASO |
BIIB080 (Biogen) |
MAPT mRNA knockdown |
Phase 2 |
Intrathecal |
| Antibody |
E2814 (Eisai) |
Tau protein binding |
Phase 2/3 |
IV |
| Antibody |
Gosuranemab (Roche) |
Tau protein binding |
Phase 2 |
IV |
| Small Molecule |
OGA Inhibitors |
Tau O-GlcNAcylation |
Phase 2 |
Oral |
- TRiM™ Platform: Novel delivery technology
- Subcutaneous Administration: Patient-friendly dosing
- Gene-Level Targeting: Addresses tau at source
- Extended Dosing: Less frequent administration
ARO-MAPT-SC has received fast track designation, which:
- Facilitates frequent communication with FDA
- Allows rolling review of data
- Provides guidance on accelerated approval pathways
- Recognizes unmet need in AD treatment
The development strategy incorporates:
- Surrogate Endpoints: CSF tau as predictive biomarker
- Accelerated Approval: Potential for earlier approval based on biomarkers
- Confirmatory Trials: Post-approval studies for clinical endpoints
ARO-MAPT-SC may be combined with other approaches:
- Anti-Amyloid Therapies: Lecanemab, donanemab
- Anti-Neuroinflammation: Microglial modulators
- Symptomatic Treatments: AChEIs, NMDA antagonists
Beyond treatment, RNAi could enable prevention:
- Preclinical Intervention: Treatment before symptoms
- Genetic Risk Carriers: APOE4 homozygotes, PSEN1 carriers
- Primary Prevention: Population-based approaches